Brief: First Wave Biopharma Chairman And CEO Issues Letter To Stockholders
16/11/2022 12:07
Nov 16 (Reuters) - First Wave BioPharma Inc FWBI.O :
* FIRST WAVE BIOPHARMA CHAIRMAN AND CEO ISSUES LETTER TO
STOCKHOLDERS
* FIRST WAVE BIOPHARMA INC - EXPECT TO FILE AN IND
APPLICATION
WITH FDA TO EVALUATE AN ENHANCED ENTERIC MICROGRANULE DELIVERY
FORMULATION OF ADRULIPASE
* FIRST WAVE BIOPHARMA INC - EXPECTS TO INITIATE ADRULIPASE
PHASE
2 CLINICAL TRIAL PRIOR TO YEAR-END 2022 WITH TOP-LINE DATA
ANTICIPATED BY END H1 2023
Source text for Eikon: ID:nGNX3m0sxJ
Further company coverage: FWBI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GridAI Technologies
See all newsBrief: Gridai Technologies Corp - Enters $2.54 Million Private Placement Of Shares And Warrants - SEC Filing
Brief: IBN Announces Latest Episode Of The Techmediawire Podcast Featuring Marshall Chapin, CEO Of Grid Ai Corp.
Brief: Entero Therapeutics Terminated Interim CEO And Chairman Richard Joel Paolone Effective Immediately - SEC Filing
Brief: Entero Therapeutics Inc - Now Offering 15.2 Million Shares Of Common Stock
Brief: Entero Therapeutics Inc Subsidiary Immunogenx Enters Settlement Agreement